88 results
8-K
STRO
Sutro Biopharma Inc
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
herein has been prepared by, and is the responsibility of, the Company’s management. The Company’s independent registered public accounting firm has
8-K
EX-99.1
wwewrbg8
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
8-K
EX-99.2
e5tz6 656zd
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am
8-K
EX-99.1
6hwoa4sz3a1phk
7 May 21
Business Highlights and 2021 Anticipated Milestones
7:00am
8-K
EX-99.1
lxawxz 2vdjf8
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
8-K
EX-99.2
185gwj 7f54
9 Sep 20
Other Events
5:23pm
8-K
EX-99.2
s1s9vdz
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
424B5
bzj7malwwojwmb
2 Apr 24
Prospectus supplement for primary offering
4:58pm
PRE 14A
oanbb
14 Apr 23
Preliminary proxy
4:05pm
8-K
EX-99.2
he2spu
19 May 21
Regulation FD Disclosure
5:00pm
8-K
EX-99.1
bqlg1ga9
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
POSASR
EX-5.1
4hf4i swcokoeql
28 Feb 22
Automatic shelf registration (post-effective amendment)
4:16pm
POS AM
EX-5.1
qca8 8n5jml938t16
28 Feb 22
Prospectus update (post-effective amendment)
5:46pm